Targeted Drug Tagrisso Could Be Advance Against Lung Cancer
MONDAY, Feb. 6, 2023 (HealthDay News) — The best treatment for a genetically driven form of lung cancer continues to show lasting benefits, a new clinical trial update shows. Tagrisso (osimertinib) nearly doubles disease-free survival in earlier-stage patients whose lung cancer is driven by a mutation in their EGFR (epidermalContinue Reading














